Monday, October 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 25, 2026

SpaceX Is A 'Money Furnace,' Former Hedge Fund Manager Says As Filing Reveals $4.3 Billion Quarterly Loss

View original at finance.yahoo.com
SpaceX Is A 'Money Furnace,' Former Hedge Fund Manager Says As Filing Reveals $4.3 Billion Quarterly Loss Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • There is a 94% probability of SpaceX completing its stock market listing in June 2026

    60% confidence

  • Anthropic has agreed to pay SpaceX approximately $1.25 billion a month to rent capacity at its Colossus data centers through 2029

    60% confidence

  • SpaceX has lost approximately $37 billion since inception

    60% confidence

  • SpaceX's valuation is the most extreme of any company imaginable, exceeding even Nvidia's despite Nvidia being hugely profitable with massive margins while SpaceX is not profitable

    60% confidence

  • There is an 87% probability that SpaceX will deliver 2026's biggest IPO

    60% confidence

  • SpaceX plans to build solar-powered data centers in orbit to sidestep terrestrial power and cooling constraints

    60% confidence

  • SpaceX is a 'money furnace'

    60% confidence

  • SpaceX's plans for solar-powered data centers in orbit make it look more like a science experiment than a business

    60% confidence

Data points we hold from this source

Anthropic · data center monthly spend1.25 USD
SpaceX · ipo float percent5 percent
SpaceX · space division operating loss-662 USD
SpaceX · cumulative net loss-37 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com